Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Reports Q3 2023 Financial ResultsNovember 14, 2023

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.

Emmaus Life Sciences Reports Management ChangesAugust 23, 2023

Emmaus today reported that on August 18, 2023, the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board.

Emmaus Life Sciences Reports Q2 2023 Financial ResultsAugust 14, 2023

Emmaus Life Sciences, Inc. today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.

Emmaus Life Sciences Receives Marketing Authorization for Endari® in OmanJuly 13, 2023

Emmaus today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari®

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRAMay 31, 2023

Emmaus has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain.